KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Research & Development (2018 - 2025)

Historic Research & Development for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $13.0 million.

  • Castle Biosciences' Research & Development rose 516.92% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year decrease of 592.17%. This contributed to the annual value of $52.0 million for FY2024, which is 294.12% down from last year.
  • Latest data reveals that Castle Biosciences reported Research & Development of $13.0 million as of Q3 2025, which was up 516.92% from $12.8 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Research & Development high stood at $14.4 million for Q1 2023, and its period low was $5.9 million during Q1 2021.
  • Over the past 5 years, Castle Biosciences' median Research & Development value was $12.3 million (recorded in 2024), while the average stood at $11.5 million.
  • As far as peak fluctuations go, Castle Biosciences' Research & Development surged by 15122.04% in 2021, and later crashed by 954.3% in 2025.
  • Quarter analysis of 5 years shows Castle Biosciences' Research & Development stood at $9.4 million in 2021, then grew by 19.74% to $11.3 million in 2022, then rose by 14.9% to $13.0 million in 2023, then dropped by 9.4% to $11.8 million in 2024, then increased by 10.08% to $13.0 million in 2025.
  • Its Research & Development stands at $13.0 million for Q3 2025, versus $12.8 million for Q2 2025 and $12.6 million for Q1 2025.